AR117255A1 - Formas cristalinas de un inhibidor de mcl-1, un proceso para su preparación y composiciones farmacéuticas que las contienen - Google Patents
Formas cristalinas de un inhibidor de mcl-1, un proceso para su preparación y composiciones farmacéuticas que las contienenInfo
- Publication number
- AR117255A1 AR117255A1 ARP190103554A ARP190103554A AR117255A1 AR 117255 A1 AR117255 A1 AR 117255A1 AR P190103554 A ARP190103554 A AR P190103554A AR P190103554 A ARP190103554 A AR P190103554A AR 117255 A1 AR117255 A1 AR 117255A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- crystalline forms
- mcl
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formas cristalinas del Compuesto A de fórmula (1) caracterizadas por su diagrama de difracción de rayos X de polvo, espectro RMN ¹³C en estado sólido, espectro de MIR y espectro de Raman y composiciones farmacéuticas que las contienen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634 | 2018-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117255A1 true AR117255A1 (es) | 2021-07-21 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103554A AR117255A1 (es) | 2018-12-06 | 2019-12-05 | Formas cristalinas de un inhibidor de mcl-1, un proceso para su preparación y composiciones farmacéuticas que las contienen |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12129261B2 (es) |
| EP (1) | EP3891156B1 (es) |
| JP (1) | JP7649241B2 (es) |
| KR (1) | KR102855345B1 (es) |
| CN (1) | CN113166169A (es) |
| AR (1) | AR117255A1 (es) |
| AU (1) | AU2019391329B2 (es) |
| BR (1) | BR112021010072A2 (es) |
| CA (1) | CA3121363A1 (es) |
| DK (1) | DK3891156T3 (es) |
| EA (1) | EA202191534A1 (es) |
| ES (1) | ES2971258T3 (es) |
| FI (1) | FI3891156T3 (es) |
| HR (1) | HRP20240211T1 (es) |
| HU (1) | HUE065266T2 (es) |
| IL (1) | IL283656B2 (es) |
| LT (1) | LT3891156T (es) |
| MA (1) | MA54379B1 (es) |
| MD (1) | MD3891156T2 (es) |
| MX (1) | MX2021006702A (es) |
| PL (1) | PL3891156T3 (es) |
| PT (1) | PT3891156T (es) |
| RS (1) | RS65047B1 (es) |
| SI (1) | SI3891156T1 (es) |
| WO (1) | WO2020115183A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240019330A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항체 약물 접합체의 조합 |
| CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/en not_active Ceased
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/en active Active
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 IL IL283656A patent/IL283656B2/en unknown
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 AU AU2019391329A patent/AU2019391329B2/en active Active
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 US US17/295,521 patent/US12129261B2/en active Active
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
- 2019-12-05 MD MDE20210991T patent/MD3891156T2/ro unknown
- 2019-12-05 KR KR1020217020808A patent/KR102855345B1/ko active Active
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 CA CA3121363A patent/CA3121363A1/en active Pending
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 JP JP2021531796A patent/JP7649241B2/ja active Active
-
2024
- 2024-09-24 US US18/894,074 patent/US20250011337A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003154A1 (es) | Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079) | |
| MX2019015744A (es) | Composiciones farmaceuticas. | |
| MX390287B (es) | Composiciones farmacéuticas que contienen derivados de piridona policíclicos sustituidos y profármacos de los mismos. | |
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| MX372716B (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| MX376028B (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR104505A1 (es) | Formas sólidas | |
| ECSP088114A (es) | Nuevos derivados de la 2-azetidinona y su uso como inhibidores de absorción del colesterol para el tratamiento de hiperlipidemia | |
| CO2019013823A2 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
| EA201591530A1 (ru) | Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции | |
| CO2020001346A2 (es) | Pirrolopirimidina y derivados de pirrolopirimidina | |
| UY39153A (es) | Metilación de compuestos mcl-1 | |
| AR117255A1 (es) | Formas cristalinas de un inhibidor de mcl-1, un proceso para su preparación y composiciones farmacéuticas que las contienen | |
| CO2024013531A2 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
| MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
| CL2020000376A1 (es) | Compuesto pentacíclico. | |
| GEAP202215389A (en) | Polymorphs | |
| CO2022009260A2 (es) | Composiciones farmacéuticas oftálmicas | |
| CL2021000947A1 (es) | Nueva sal de un inhibidor de bcl-2, forma cristalina relacionada, método para preparar la misma y composiciones farmacéuticas que contienen la misma. | |
| CL2021000973A1 (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| CL2021000663A1 (es) | Proceso para la producción de gas de síntesis. | |
| ECSP22046595A (es) | Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina |